By Elana Gotkine HealthDay Reporter<\/b><\/p>\n <\/b><\/p>\n THURSDAY, Aug. 17, 2023 (HealthDay News) — Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome\/acute myeloid leukemia (tMDS\/AML), although risks have been lower in more recent years, according to a study published in the July issue of eClinicalMedicine<\/em>.<\/p>\n Lindsay M. Morton, Ph.D., from the National Cancer Institute in Bethesda, Maryland, and colleagues identified 1,496 tMDS\/AML cases among 186,503 adults who were treated with initial chemotherapy\/immunotherapy for first primary LN and survived one year or longer.<\/p>\n The researchers found that the highest risks for tMDS\/AML occurred after precursor leukemia\/lymphoma (standardized incidence ratio [SIR], 39; excess absolute risks [EAR], 30 per 10,000 person-years), Burkitt leukemia\/lymphoma (SIR, 20; EAR, 24), peripheral T-cell lymphoma (SIR, 12; EAR, 23), chronic lymphocytic leukemia\/small lymphocytic lymphoma (SIR, 9.0; EAR, 27), and mantle cell lymphoma (SIR, 8.5; EAR, 25). After all other LN subtypes except hairy cell leukemia and mycosis fungoides\/S \u00a9zary syndrome, elevated risks were also observed (SIRs, 4.2 to 6.9; EARs, 4.9 to 15). For patients treated more recently, tMDS\/AML risks were significantly higher after chronic lymphocytic leukemia\/small lymphocytic lymphoma (SIR2000-2005<\/sub>, 4.8; SIR2012-2017<\/sub>, 10), significantly lower after Hodgkin (SIR2000-2005<\/sub>, 15; SIR2012-2017<\/sub>, 6.3) and marginal zone (SIR2000-2005<\/sub>, 7.5; SIR2012-2017<\/sub>, 2.3) lymphomas, and nonsignificantly lower after mantle cell lymphoma, lymphoplasmacytic lymphoma\/Waldenstr \u00b6m macroglobulinemia, and plasma cell neoplasms. Trends for EAR and cumulative incidence were generally similar to those of SIR. Median survival was 8.0 months after tMDS\/AML.<\/p>\n “Population-based data show that patients treated with initial chemo\/immunotherapy for most lymphoid neoplasms may face increased tMDS\/AML risks, but that tMDS\/AML risks have evolved consistent with changes in treatment practices for certain subtypes,” the authors write.<\/p>\n<\/del>Risks for therapy-related myelodysplastic syndrome\/acute myeloid leukemia elevated, but risks lower in recent years<\/p>\n<\/h3>\n